ACADIA Pharmaceuticals (Nasdaq: ACAD) $7.97. Today announced that the U.S. Food and Drug Administration (FDA) has agreed that the data from the pivotal Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing of a New Drug Application (NDA) for the treatment of Parkinson’s disease psychosis (PDP). As a result, ACADIA will no longer conduct the Phase III -021 study that was planned as a confirmatory trial and was scheduled to be initiated later this month.
What They Do: ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders.
Aeterna Zentaris (Nasdaq: AEZS) $1.90. Announced Wednesday after market close encouraging updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models. Results further showed the compounds' high potential for the treatment of luteinizing hormone-releasing hormone ("LHRH") receptor positive tumors. Data were presented earlier today by Babette Aicher, PhD, the Company's Director of Preclinical Development, during a poster presentation at the American Association for Cancer Research ("AACR") annual meeting currently being held in Washington D.C. The study is funded through a grant from the German Ministry of Education and Research.
Juergen Engel, PhD, Aeterna Zentaris President and CEO stated, "Disorazol Z cytotoxic conjugates such as AEZS-125 and AEZS-138 are an extension of our AEZS-108 innovative LHRH-targeted platform in oncology. These results confirm the encouraging data presented at the ENA Symposium in November 2012 , and will enable us to better select a specific drug candidate for further preclinical development expected to start during this quarter."
What They Do: Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs.
Zumiez (Nasdaq: ZUMZ) $234.90. Announced Wednesday after market close that total net sales for the five-week period ended April 6, 2013 increased 19.7% to $61.0 million, compared to $50.9 million for the five-week period ended March 31, 2012. The Company's comparable store sales increased 2.1% for the five-week period ended April 6, 2013 compared to a comparable store sales increase of 14.1% for the five-week period ended March 31, 2012.
What They Do: Zumiez is a leading multi-channel specialty retailer of action sports related apparel, footwear, equipment and accessories, focusing on skateboarding, snowboarding, surfing, motocross and BMX for young men and women.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter.